A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
Launched by OXFORD BIODYNAMICS INC. · Oct 9, 2024
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called PROWES, is exploring whether a blood test known as Episwitch CiRT® can help doctors predict how well patients with advanced cancer will respond to a specific type of cancer treatment called PD-(L)-1 checkpoint inhibitors. These treatments work by helping the immune system recognize and attack cancer cells. The study aims to compare the test results with the actual responses of patients to the treatment, which could help improve future cancer care.
To participate in this trial, individuals must be at least 18 years old, have stage III or IV cancer, and have been selected by their healthcare provider to take the Episwitch CiRT® test. They should also be able to understand the study details and provide written consent. Participants can expect to undergo the blood test as part of their usual care and may receive PD-(L)-1 treatment if they qualify. It’s important to note that individuals who are pregnant, breastfeeding, or have certain medical histories may not be eligible for this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. 18 years of age or older
- • 2. Stage III or IV cancer
- • 3. Selected by their healthcare provider to receive the Episwitch CiRT® test according to the current evidence-based schedule (per protocol) as part of their standard of practice.
- • 4. ECOG performance status ≤ 2
- • 5. Clinically eligible for ICI therapy
- • 6. Able to read, understand and provide written informed consent.
- • 7. Willing and able to comply with the study requirements
- Exclusion Criteria:
- • 1. Pregnant or breastfeeding
- • 2. History of bone marrow or organ transplant
- • 3. Contra indication for receiving Immune Check Point inhibitor.
About Oxford Biodynamics Inc.
Oxford Biodynamics Inc. is a pioneering biotechnology company specializing in the development of innovative epigenetic biomarkers for the early detection and monitoring of diseases, particularly cancer. Utilizing advanced proprietary technology, the company aims to transform diagnostic processes by providing non-invasive, highly accurate tests that enhance patient outcomes and facilitate personalized medicine. Committed to scientific excellence and collaboration, Oxford Biodynamics is at the forefront of integrating cutting-edge research with clinical applications, striving to improve healthcare solutions and contribute to the advancement of precision diagnostics.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dublin, Georgia, United States
Rock Hill, South Carolina, United States
Norwich, Connecticut, United States
Patients applied
Trial Officials
Ryan Mathis, MD
Study Director
Oxford BioDynamics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported